ConductScience.org, home

Paper31136799

Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement.

McCune JS and 22 others. Biol Blood Marrow Transplant, 2019. Cited by 26 papers, by iCite.

Cite this record

ConductScience Library. Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement. Papers, record 31136799. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31136799

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement.
PubMed
Journal
Biol Blood Marrow Transplant
PubMed
Year
2019
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Consensus Statement
PubMed
Citations, by iCite
26
iCite
Relative citation ratio, by iCite
1.7
iCite
Revised in PubMed
2026-03-04
PubMed

Authors23

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1McCune JSJeannine S
2Quinones CMChristine M
3Ritchie JJames
4Carpenter PAPaul A
5van Maarseveen EErik
6Yeh RFRosa F
7Anasetti CClaudio
8Boelens JJJaap J
9Hamerschlak NNelson
10Hassan MMoustapha
11Kang HJHyoung Jin
12Kanda YYoshinobu
13Paci AAngelo
14Perales MAMiguel-Angel
15Shaw PJPeter J
16Seewaldt VLVictoria L
17Savani BNBipin N
18Hsieh AAngela
19Poon BBetsy
20Mohty MMohamad

Source PubMed

See all 23 authorsDownload CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
BusulfanMajor topic
Databases, FactualMajor topic
Drug MonitoringMajor topic
Hematopoietic Stem Cell TransplantationMajor topic
RegistriesMajor topic
Allografts
Female
Humans
Male

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA033572NCI NIH HHSUnited StatesP30CA033572PubMed and NIHNIH RePORTER
R01 CA182963NCI NIH HHSUnited StatesR01CA182963PubMed and NIHNIH RePORTER
U54 HD083211NICHD NIH HHSUnited StatesU54HD083211PubMed and NIHNIH RePORTER

Download CSV of grants

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in32407883Letter to the Editor Regarding "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement".https://conductscience.org/library/papers/32407883PubMed
Comment in32531439Response to Kawedia et al Letter to Editor in Response to the Article by McCune Et Al "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement".https://conductscience.org/library/papers/32531439PubMed

Download CSV of comments and corrections

References33

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110800058An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease.Bone Marrow Transplant2000https://conductscience.org/library/papers/10800058PubMed
210976660Plasma concentration monitoring of busulfan: does it improve clinical outcome?Clin Pharmacokinet2000https://conductscience.org/library/papers/10976660PubMed
311148943A continuous-improvement approach for reducing the number of chemotherapy-related medication errors.Am J Health Syst Pharm2000https://conductscience.org/library/papers/11148943PubMed
411781609Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation.Bone Marrow Transplant2001https://conductscience.org/library/papers/11781609PubMed
512149198Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.Blood2002https://conductscience.org/library/papers/12149198PubMed
612189535Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation.Bone Marrow Transplant2002https://conductscience.org/library/papers/12189535PubMed
712595317HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen.Blood2003https://conductscience.org/library/papers/12595317PubMed
816321161Stability of response characteristics of a Delphi panel: application of bootstrap data expansion.BMC Med Res Methodol2005https://conductscience.org/library/papers/16321161PubMed
916332558The Delphi technique in health sciences education research.Med Teach2005https://conductscience.org/library/papers/16332558PubMed
1016641398Hematopoietic stem-cell transplantation.N Engl J Med2006https://conductscience.org/library/papers/16641398PubMed
1118215782High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.Biol Blood Marrow Transplant2008https://conductscience.org/library/papers/18215782PubMed
1218929686Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.J Biomed Inform2009https://conductscience.org/library/papers/18929686PubMed
1319611402Busulfan in hematopoietic stem cell transplant setting.Expert Opin Drug Metab Toxicol2009https://conductscience.org/library/papers/19611402PubMed
1422067636Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs.BMC Cancer2011https://conductscience.org/library/papers/22067636PubMed
1522198540Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation.Biol Blood Marrow Transplant2012https://conductscience.org/library/papers/22198540PubMed
1622742881Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial.Eur J Cancer2012https://conductscience.org/library/papers/22742881PubMed
1723581955Mass or molar? Recommendations for reporting concentrations of therapeutic drugs.Med J Aust2013https://conductscience.org/library/papers/23581955PubMed
1823871781Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation.Biol Blood Marrow Transplant2013https://conductscience.org/library/papers/23871781PubMed
1924001695Harmonization of laboratory testing - Current achievements and future strategies.Clin Chim Acta2014https://conductscience.org/library/papers/24001695PubMed
2024120352Promoting clinical and laboratory interaction by harmonization.Clin Chim Acta2014https://conductscience.org/library/papers/24120352PubMed

See all 33 referencesDownload CSV of references

Cited by18

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.

PMIDTitleJournalYearIn PapersSource
41904243
Reduced relapse rate and improved GVHD/relapse free survival (GRFS) with pharmacokinetics-guided busulfan conditioning regimen for allogeneic stem cell transplantation in adult patients with myeloid hematologic malignancies.
Bone Marrow Transplant2026https://conductscience.org/library/papers/41904243PubMed
41779961Refining busulfan exposure enhances pediatric ALL HSCT outcomes: insights from the International FORUM study.Blood Adv2026https://conductscience.org/library/papers/41779961PubMed
39932505New approach to busulfan dosing in infants and children based on a population pharmacokinetic analysis.Cancer Chemother Pharmacol2025https://conductscience.org/library/papers/39932505PubMed
39625679Comparison of busulfan pharmacokinetics between four-times-daily and once-daily administration in pediatric patients: a preliminary prospective observational trial.Int J Hematol2025https://conductscience.org/library/papers/39625679PubMed
39368808The promises and potential pitfalls of pharmacokinetic model-based dosing in cellular therapy.Blood Adv2024https://conductscience.org/library/papers/39368808PubMed
39271948A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT).Bone Marrow Transplant2024https://conductscience.org/library/papers/39271948PubMed
39074263Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity.Blood Adv2024https://conductscience.org/library/papers/39074263PubMed
37415003Population Pharmacokinetic Model of Intravenous Busulfan in Hematopoietic Cell Transplantation: Systematic Review and Comparative Simulations.Clin Pharmacokinet2023https://conductscience.org/library/papers/37415003PubMed
37379285Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation.Blood Adv2023https://conductscience.org/library/papers/37379285PubMed
36369996Prediction of Busulfan Clearance by Predose Plasma Metabolomic Profiling.Clin Pharmacol Ther2023https://conductscience.org/library/papers/36369996PubMed
35330826Therapeutic Drug Monitoring of Conditioning Agents in Pediatric Allogeneic Stem Cell Transplantation; Where do We Stand?Front Pharmacol2022https://conductscience.org/library/papers/35330826PubMed
34956984Total Body Irradiation Forever? Optimising Chemotherapeutic Options for Irradiation-Free Conditioning for Paediatric Acute Lymphoblastic Leukaemia.Front Pediatr2021https://conductscience.org/library/papers/34956984PubMed
34664209Evaluation of the Robustness of Therapeutic Drug Monitoring Coupled with Bayesian Forecasting of Busulfan with Regard to Inaccurate Documentation.Pharm Res2021https://conductscience.org/library/papers/34664209PubMed
34453497Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study.CPT Pharmacometrics Syst Pharmacol2021https://conductscience.org/library/papers/34453497PubMed
33128207Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients.Clin Pharmacokinet2021https://conductscience.org/library/papers/33128207PubMed
32229032Using big data in pediatric oncology: Current applications and future directions.Semin Oncol2020https://conductscience.org/library/papers/32229032PubMed
32140913Population pharmacokinetics of busulfan in Saudi pediatric patients undergoing hematopoietic stem cell transplantation.Int J Clin Pharm2020https://conductscience.org/library/papers/32140913PubMed
32077123Modelling of neutrophil dynamics in children receiving busulfan or treosulfan for haematopoietic stem cell transplant conditioning.Br J Clin Pharmacol2020https://conductscience.org/library/papers/32077123PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/31136799

GET https://conductscience.org/api/papers/v1/31136799/authors?page=2